Zhu Ning, Dong Caixia, Weng Shanshan, Yuan Ying, Yuan Ying
Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Province, China.
Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Province, China.
J Coll Physicians Surg Pak. 2019 Dec;29(12):S126-S128. doi: 10.29271/jcpsp.2019.12.S126.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for patients with advanced non-small-cell lung cancer (NSCLC) harbouring common EGFR mutations. However, about 10% of EGFR mutations are uncommon mutations and their response to EGFR-TKIs remains unclear. The present case reports a 75-year, female patient with advanced NSCLC, presenting with a new subtype of EGFR exon 19 insertion mutation (IPVAIL insertion), who showed obvious symptom improvement after EGFR-TKIs treatment but a relatively short time of progression-free survival (PFS) and succumbed to tumor 133 days (4.4 months) after diagnosis. In conclusion, patients harbouring new subtype of EGFR exon 19 insertion mutations, IPVAIL insertion may have a poor prognosis. Further experiences are required to characterise these uncommon mutations.
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）是晚期非小细胞肺癌（NSCLC）伴有常见EGFR突变患者的标准治疗方法。然而，约10%的EGFR突变是罕见突变，它们对EGFR-TKIs的反应仍不清楚。本病例报告了一名75岁女性晚期NSCLC患者，其存在一种新的EGFR外显子19插入突变亚型（IPVAIL插入），该患者在接受EGFR-TKIs治疗后症状明显改善，但无进展生存期（PFS）相对较短，诊断后133天（4.4个月）死于肿瘤。总之，携带新的EGFR外显子19插入突变亚型IPVAIL插入的患者预后可能较差。需要更多经验来明确这些罕见突变的特征。
